150-Year Lifespan? Scientists Draw The Line

Scientists in lab coats reviewing data on a computer — Photo: Alexander Raths / Shutterstock

Scientists now have a number to argue about: 150 years, the age at which the human body may simply run out of road, according to new research feeding a booming AI-driven push to extend life.

Quick Take

A study of more than 540,000 people pins a possible upper limit on human lifespan near 150 years.
An AI-designed drug called rentosertib reversed signs of biological aging in a small clinical trial.
The Food and Drug Administration (FDA) still does not treat aging itself as a disease it can approve drugs for.
Billions in investment and new federal research grants are chasing the gap between what AI promises and what it has proven.

A Number Pulled From Half a Million Lives

Researchers at the biotech firm Gero and Roswell Park Comprehensive Cancer Center built their estimate from a massive pile of data. They studied health and fitness records from more than 540,000 volunteers, then checked their findings against a second group of over 4,500 people. The pattern that emerged showed the body’s ability to bounce back from illness and stress fading out almost completely somewhere between ages 120 and 150, according to a European Union research summary of the work.

That window is not a guess pulled from science fiction. It is a statistical boundary, built the same way actuaries calculate life insurance tables, just aimed much further out than anyone has lived. The oldest confirmed human on record, Jeanne Calment of France, died at 122. The new research suggests biology itself, not disease or accident, eventually closes the door around 150.

That gap between 122 and 150 is exactly where the AI-powered longevity industry has planted its flag, betting that machine learning can find ways to push the ceiling closer to its theoretical limit.

A Drug Designed By Algorithm Enters The Clinic

The clearest real-world test case so far comes from Insilico Medicine, a company using artificial intelligence to design drug molecules from scratch. Its candidate, rentosertib, was built entirely through AI-driven discovery and then tested in a Phase IIa clinical trial on 42 participants. Researchers measured biological age using six separate, independently developed aging clocks built on blood protein data, and found the drug appeared to reverse the aging signal while lung function improved along with the dose.

That result matters because it is one of the first times an AI-discovered drug has shown a measurable anti-aging effect in actual human patients, not mice or cell cultures. It does not mean a pill that adds decades to a lifespan is close to pharmacy shelves. It means the pipeline connecting AI prediction to human results finally produced a visible signal worth studying further.

Why The FDA Still Won’t Approve An “Anti-Aging” Pill

Here is the catch nobody in Silicon Valley likes to lead with. The FDA does not classify aging as a disease. It treats aging as a natural process, which means there is no approval pathway for a drug that simply claims to slow it down. Companies instead have to aim their trials at a specific age-related disease, like lung scarring or a particular cancer, and hope the anti-aging benefit shows up as a side effect regulators can measure.

That regulatory reality is why no longevity company today sits close to winning approval for an aging drug itself. Yet the broader drug industry around them is moving fast. The FDA approved 50 new drugs in 2024 and 46 in 2025, including what researchers are calling the first class of cellular longevity therapeutics, while pharmaceutical giants spent more than 65 billion dollars buying up biotech companies through October of 2025.

Government Money Joins The Race

Washington is placing its own bet now too. Federal health research has committed up to 144 million dollars over five years to seven research teams working on biomarkers, tests, and treatments aimed at keeping people functional longer, not just alive longer. A Stanford Medicine team alone received up to 34 million dollars to build a scoring tool that measures a person’s physical and mental capacity, then test whether early intervention can preserve it.

The Honest Math Behind The Hype

None of this should be read as a countdown to 150-year lifespans arriving on schedule. Across the drug industry broadly, roughly 90 percent of candidates that enter clinical trials never reach approval, and AI has not yet changed that basic math in a meaningful way. No gerotherapeutic drug, meaning one specifically designed to slow aging itself, has ever been proven in humans to extend lifespan or won approval for an aging-related use.

What has changed is the speed and seriousness of the search. A credible peer-reviewed estimate now exists for how long a human body can theoretically last. A real drug built by artificial intelligence has shown a real signal in real patients. Federal agencies are funding the measurement tools scientists will need to prove whether any of it actually works. That is not immortality. It is the opening chapter of a genuinely new chase.